Drugmakers Dramatically Boosted Lobbying Spending In Trump’s First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Drugs
1,161-1,180 of 1,325 results
-
-
Marathon Pharmaceutical Drops Out Of PhRMA Following Drug Price Controversy
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
-
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
-
Letters to the Editor
Readers: Training Patients To Advocate For Their Illnesses Is ‘A Virtue Not A Sin’
Kaiser Health News gives readers a chance to respond, react and comment on our stories.
-
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
By Emily Kopp and Rachel Bluth -
Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
-
California Presses Forward In Fight To Regulate Pharma
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
-
The Orphan Drug Machine
Drugmakers Help Turn Patients With Rare Diseases Into D.C. Lobbyists
Amplifying the "patient voice," those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
-
Another Circle Of Hell: Surviving Opioids In The Fentanyl Era
Unlike heroin, fentanyl routinely shuts down breathing in seconds, and it's becoming more common.
-
Ask Emily
In Pain? Many Doctors Say Opioids Are Not The Answer
The opioid addiction crisis has led to a crackdown on prescriptions for chronic pain patients, who are increasingly given less addictive painkillers along with referrals for acupuncture, physical therapy, massage and even yoga.
By Emily Bazar -
New Vaccine Recommendation Cuts Number Of HPV Shots Children Need
The vaccine protects kids against infection and several types of cancer but many parents have been reluctant to use it for their children.
-
Trump’s Promise To Rein In Drug Prices Could Open Floodgate To Importation Laws
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
By Rachel Bluth -
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
-
Prescription Drug Costs Are On The Rise; So Are The TV Ads Promoting Them
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
By Bruce Horovitz and Julie Appleby -
Cholesterol Drug Prevents Heart Attacks — But It Doesn’t Come Cheap
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
By Liz Szabo -
$89,000 Orphan Drug Gets A New Owner — And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
-
Treating Cancer: Hope Vs. Hype
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
By Liz Szabo -
Repeal & Replace Watch
By The Numbers: Trump’s Choice For FDA Chief Is Versatile, Entrenched In Pharma
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
-
HMO Doctors Take Pains To Slash Opioid Prescriptions
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
By Sam Quinones -
To Save On Drug Costs, Insurer Wants To Steer You To ‘Preferred’ Pharmacies
Blue Shield of California is hoping to steer consumers to "preferred" pharmacies where drugs are cheaper and copays lower.